Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (10265)	5/28/1999 11:15:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

O.K. Robert, thanks for the post and information. The only part I don't understand is why you think the 4 is incorrect. What do you mean the 4 is incorrect? In addition to the 62 deaths of non enrolled there were 4 immediate deaths among the 34 that had been enrolled. Castello mentioned this as a caution to thinking there were zero deaths in the treatment arm. Martin said this can be a typical problem in any trial where the illness is often fatal and again demonstrates the need to have a trial with sufficient power. Given all the sidebars about why it was said, how it is a common problem and how it demonstrates the need for power, I find my understanding of what was said about the "4" more apt to be correct than your blunt non reason provided, "4 is incorrect" BTW did you discuss I-Prex with Martin? If so than does this mean it's not close? How long do we have to wait for these liver results? If one would have only one drink per day while waiting for them I think one would have their own liver problem. Stop picking on that guy on Yahoo that was kind enough to let the rest of know what was said at the annual meeting. Since none of us know if any of us are telling the truth, we live with this, and it sounds harsh when raised selectively.